PDF herunterladen
Nuklearmedizin 2016; 55(03): 104-114
DOI: 10.3413/Nukmed-0742-15-05
Original article
Schattauer GmbH

Dynamic 68Ga-DOTATOC PET/CT and static image in NET patients

Correlation of parameters during PRRTDynamische und statische 68Ga-DOTATOC-PET/CT bei Patienten mit NETKorrelation der Parameter während der PRRT
Sofie Van Binnebeek
1   Nuclear Medicine, University Hospitals Leuven and Department of Imaging & Pathology, KU Leuven
,
Michel Koole
1   Nuclear Medicine, University Hospitals Leuven and Department of Imaging & Pathology, KU Leuven
,
Christelle Terwinghe
1   Nuclear Medicine, University Hospitals Leuven and Department of Imaging & Pathology, KU Leuven
,
Kristof Baete
1   Nuclear Medicine, University Hospitals Leuven and Department of Imaging & Pathology, KU Leuven
,
Bert Vanbilloen
1   Nuclear Medicine, University Hospitals Leuven and Department of Imaging & Pathology, KU Leuven
,
Karine Haustermans
2   Radiation Oncology, University Hospitals Leuven and Department of Oncology, KU Leuven
,
Paul M. Clement
3   General Medical Oncology, University Hospitals Leuven and Department of Oncology, KU Leuven
,
Kris Bogaerts
4   Department of Public Health and primary Care (I-BioStat), KU Leuven
,
Alfons Verbruggen
5   Laboratory for Radiopharmacy, KU Leuven
,
Kris Nackaerts
6   Pulmonology, University Hospitals Leuven
,
Eric Van Cutsem
7   Division of Digestive Oncology, University Hospitals Leuven and Department of Oncology, KU Leuven
,
Chris Verslype
7   Division of Digestive Oncology, University Hospitals Leuven and Department of Oncology, KU Leuven
,
Felix M. Mottaghy
8   Department of Nuclear Medicine, Maastricht University Medical Center, Maastricht, The Netherlands
9   Department of Nuclear Medicine, University Hospital Aachen, Germany
,
Christophe M. Deroose
1   Nuclear Medicine, University Hospitals Leuven and Department of Imaging & Pathology, KU Leuven
› Institutsangaben
Weitere Informationen

Publikationsverlauf

received: 21. Mai 2015

accepted in revised form: 12. Januar 2016

Publikationsdatum:
06. März 2018 (online)

    Lizenzen und Reprints

Summary

Purpose: To investigate the relationship between the dynamic parameters (Ki) and static image-derived parameters of 68Ga-DOTATOC-PET, to determine which static parameter best reflects underlying somatostatin-receptor-expression (SSR) levels on neuroendocrine tumours (NETs). Patients, methods: 20 patients with metastasized NETs underwent a dynamic and static 68Ga-DOTATOC-PET before PRRT and at 7 and 40 weeks after the first administration of 90Y-DOTATOC (in total 4 cycles were planned); 175 lesions were defined and analyzed on the dynamic as well as static scans. Quantitative analysis was performed using the software PMOD. One to five target lesions per patient were chosen and delineated manually on the baseline dynamic scan and further, on the corresponding static 68Ga-DOTATOC-PET and the dynamic and static 68Ga-DOTATOC-PET at the other time-points; SUVmax and SUVmean of the lesions was assessed on the other six scans. The input function was retrieved from the abdominal aorta on the images. Further on, Ki was calculated using the Patlak-Plot. At last, 5 reference regions for normalization of SUVtumour were delineated on the static scans resulting in 5 ratios (SUVratio). Results: SUVmax and SUVmean of the tumoural lesions on the dynamic 68Ga-DO-TATOC-PET had a very strong correlation with the corresponding parameters in the static scan (R²: 0.94 and 0.95 respectively). SUVmax, SUVmean and Ki of the lesions showed a good linear correlation; the SUVratios correlated poorly with Ki. A significantly better correlation was noticed between Ki and SUVtumour(max and mean) (p < 0.0001). Conclusions: As the dynamic para meter Ki correlates best with the absolute SUVtumour, SUVtumour best reflects underlying SSR-levels in NETs.

Zusammenfassung

Das Ziel der Studie war das Verhältnis zwischen dem dynamischen Parameter (Ki) und statischen Parametern der 68Ga-DOTATOC-PET zu untersuchen und den statischen Parameter zu definieren, der am besten mit der Somatostatinrezeptor (SSR) Expression von neuroendokrinen Tumoren (NET) korreliert. Patienten und Methoden: 20 Patienten mit metastasierten NET erhielten eine dynamische und statische 68Ga-DOTATOC-PET vor der ersten PRRT und 7 und 40 Wochen nach der ersten Administration von 90Y-DOTATOC (insgesamt wurden 4 Zyklen geplant); 175 Läsionen wurden auf den statischen und dynamischen Bildern definiert und ausgewertet. Die quantitative Analyse wurde mit der Software PMOD durchgeführt. Eine bis fünf Zielläsionen wurden pro Patient im ersten dynamischen Scan ausgewählt, mit einer VOI versehen, welche dann auf die weiteren dynamischen und statischen Scans transferiert wurde; sowohl SUVmax als auch SUVmean wurden bestimmt. Die Input Funktion wurde aus der im Field-of-view liegenden Aorta generiert. Ki wurde mit Hilfe des Patlak-Plots berechnet. Zuletzt wurden 5 Referenzregionen für die Normalisation des SUVtumo auf den statischen Scans bestimmt, zur Bestimmung von 5 Verhältnissen (SUVratio). Ergebnisse: SUVmax und SUVmean der Tumorläsionen inden dynamischen 68Ga-DOTATOC-PET zeigten eine sehr starke Korrelation mit den entsprechenden Parametern in den statischen Scans (R²: 0,94 bzw. 0,95). SUVmax, SUVmean und Ki der Läsionen zeigte eine gute lineare Korrelation; die verschiedenen SUVratios korrelierten auf sehr niedrigem Niveau mit Ki. Eine signifikant bessere Korrelation zeigte sich zwischen Ki und SUVtumour(max and mean) (p < 0.0001). Schlussfolgerung: Der dynamische Parameter Ki korreliert am besten mit dem absoluten SUVtumour. SUVtumour reflektiert am besten den Level der SSR-Expression in NET.

Keywords

68Ga-DOTATOC PET - Ki - somatostatin receptor expression - PRRT - neuroendocrine tumour

Schlüsselwörter

68Ga-DOTATOC PET - Ki - Somatostatinrezeptor-Expression - PRRT - neuroendokriner Tumor
 

  • References

  • 1 Armani C, Catalani E, Balbarini A. et al. Expression, pharmacology, and functional role of somatostatin receptor subtypes 1 and 2 in human macrophages. J Leukoc Biol 2007; 81: 845-855.
    CrossrefPubMedGoogle Scholar
  • 2 Boellaard R, Krak NC, Hoekstra OS. et al. Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. J Nucl Med 2004; 45: 1519-1527.
    PubMedGoogle Scholar
  • 3 Buchmann I, Henze M, Engelbrecht S. et al. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2007; 34: 1617-1626.
    CrossrefPubMedGoogle Scholar
  • 4 Cascini GL, Cuccurullo V, Mansi L. The non tumour uptake of 111In-octreotide creates new clinical indications in benign diseases, but also in oncology. Q J Nucl Med Mol Imaging 2010; 54: 24-36.
    PubMedGoogle Scholar
  • 5 Ferone D, Pivonello R, Kwekkeboom DJ. et al. Immunohistochemical localization and quantitative expression of somatostatin receptors in normal human spleen and thymus: Implications for the in vivo visualization during somatostatin receptor scintigraphy. J Endocrinol Invest 2012; 35: 528-534.
    PubMedGoogle Scholar
  • 6 Gabriel M, Decristoforo C, Kendler D. et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007; 48: 508-518.
    CrossrefPubMedGoogle Scholar
  • 7 Haug AR, Auernhammer CJ, Wangler B. et al. 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. J Nucl Med 2010; 51: 1349-1356.
    CrossrefPubMedGoogle Scholar
  • 8 Henze M, Schuhmacher J, Hipp P. et al. PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas. J Nucl Med 2001; 42: 1053-1056.
    PubMedGoogle Scholar
  • 9 Henze M, Dimitrakopoulou-Strauss A, Milker-Zabel S. et al. Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas. J Nucl Med 2005; 46: 763-769.
    PubMedGoogle Scholar
  • 10 Hofmann M, Maecke H, Borner R. et al. Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: preliminary data. Eur J Nucl Med 2001; 28: 1751-1757.
    CrossrefPubMedGoogle Scholar
  • 11 Koukouraki S, Strauss LG, Georgoulias V. et al. Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging 2006; 33: 1115-1122.
    CrossrefPubMedGoogle Scholar
  • 12 Kowalski J, Henze M, Schuhmacher J. et al. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol 2003; 5: 42-48.
    PubMedGoogle Scholar
  • 13 Meyer GJ, Macke H, Schuhmacher J. et al. 68Ga-labelled DOTA-derivatised peptide ligands. Eur J Nucl Med Mol Imaging 2004; 31: 1097-1104.
    PubMedGoogle Scholar
  • 14 Modlin IM, Oberg K, Chung DC. et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008; 9: 61-72.
    CrossrefPubMedGoogle Scholar
  • 15 Ohtake T, Kosaka N, Watanabe T. et al. Noninvasive method to obtain input function for measuring tissue glucose utilization of thoracic and abdominal organs. J Nucl Med 1991; 32: 1432-1438.
    PubMedGoogle Scholar
  • 16 Pisarek H, Pawlikowski M, Kunert-Radek J. et al. SSTR1 and SSTR5 subtypes are the dominant forms of somatostatin receptor in neuroendocrine tumors. Folia Histochem Cytobiol 2010; 48: 142-147.
    PubMedGoogle Scholar
  • 17 Putzer D, Gabriel M, Henninger B. et al. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy. J Nucl Med 2009; 50: 1214-1221.
    CrossrefPubMedGoogle Scholar
  • 18 Reubi JC, Waser B, Schaer JC. et al. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 2001; 28: 836-846.
    CrossrefPubMedGoogle Scholar
  • 19 Reubi JC, Schar JC, Waser B. et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000; 27: 273-282.
    CrossrefPubMedGoogle Scholar
  • 20 Severi S, Nanni O, Bodei L. et al. Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2013; 40: 881-888.
    CrossrefPubMedGoogle Scholar
  • 21 Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med 1991; 32: 623-648.
    PubMedGoogle Scholar
  • 22 Sundin A, Garske U, Orlefors H. Nuclear imaging of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007; 21: 69-85.
    CrossrefPubMedGoogle Scholar
  • 23 Van Binnebeek S, Karges W, Mottaghy FM. Functional imaging of neuroendocrine tumors. Methods Mol Biol 2011; 727: 105-122.
    PubMedGoogle Scholar
  • 24 Van den Hoff J, Oehme L, Schramm G. et al. The PET-derived tumor-to-blood standard uptake ratio (SUR) is superior to tumor SUV as a surrogate parameter of the metabolic rate of FDG. EJNMMI Res 2013; 3: 77.
    CrossrefPubMedGoogle Scholar
  • 25 Weckbecker G, Lewis I, Albert R. et al. Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat Rev Drug Discov 2003; 2: 999-1017.
    CrossrefPubMedGoogle Scholar
  • 26 Yap JT, Guo M, Locascio T. et al. Comparison of standardized measurement of SUVmax versus a threshold-based SUVmean in cancer response assessment using GDG-PET. J Nucl Med 2010; 51 (Suppl. 02) 1178.
    Google Scholar